ReviewCancer chemotherapy and pharmacology2019

Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations.

Carmen F Nobre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.